Vision
Providing CTC intelligence for research, drug development and clinical oncology
Mission
To drive innovative CTC solutions delivering valuable and robust proteomic and genomic information
Our Parsortix platform has the potential to deliver profound improvements in clinical and health economic outcomes in the diagnosis and treatment of cancer
The patented Parsortix platform enables the capture and harvest of intact CTCs from patient blood for subsequent, user-validated analysis
The ability to monitor and analyse CTCs may transform the treatment of cancer, providing patients with personalised cancer care through a non-invasive, repeatable liquid biopsy
Discover more
Our laboratories utilise the Parsortix platform in combination with both standardised and custom assays for the analysis of epithelial and mesenchymal CTCs for biopharmaceutical and translational researchers
These assays have the potential to provide clinicians with up-to-date, clinically actionable insight into a patient’s cancer, and may result in improved clinical outcomes for those individuals
Discover more about CelLBxHealth
Parsortix Platform
The patented Parsortix platform enables the capture and harvest of intact circulating tumor cells (CTCs) from peripheral blood. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix platform for use in subsequent downstream assays.
References
- Dive C, Brady G. SnapShot: circulating tumor cells. Cell. 2017 Feb 9;168(4):742-.
- Castro-Giner F, Aceto N. Tracking cancer progression: From circulating tumor cells to metastasis. Genome Medicine. 2020 Dec;12(1):1-2.